Treatment of B-cell lymphoma using peptides - A novel concept

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Combination chemotherapy remains the major current treatment of non- Hodgkin's lymphoma. B-cell lymphoma often has tumor-specific surface immunoglobulins called idiotypes. Clinical trials using murine monoclonal anti-idiotype antibodies as a targeting approach have shown some success. I describe a novel concept of using idiotype-specific peptides as an alternative targeting approach for the treatment of B-cell lymphoma. In brief, octapeptides that bind to the surface idiotype of the B-cell lymphoma are isolated from a large synthetic peptide library (106 to 107 peptides). Once the sequence of a tumor-specific octapeptide ligand is defined, large quantities can be synthesized and conjugated with a radionuclide (such as iodine 131). This should permit highly specific destruction of lymphoma cells that bind the labeled peptide. The theoretic advantages of this approach over the previous use of anti-idiotype antibodies are addressed.

Original languageEnglish (US)
Pages (from-to)475-479
Number of pages5
JournalWestern Journal of Medicine
Volume158
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

B-Cell Lymphoma
Peptides
Immunoglobulin Idiotypes
Anti-Idiotypic Antibodies
Peptide Library
B-Cell Antigen Receptors
Combination Drug Therapy
Radioisotopes
Iodine
Non-Hodgkin's Lymphoma
Lymphoma
Neoplasms
Therapeutics
Monoclonal Antibodies
Clinical Trials
Ligands
peptide A

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of B-cell lymphoma using peptides - A novel concept. / Lam, Kit.

In: Western Journal of Medicine, Vol. 158, No. 5, 1993, p. 475-479.

Research output: Contribution to journalArticle

@article{69aa2dbcd42b4dc7af4fe6623de74fa9,
title = "Treatment of B-cell lymphoma using peptides - A novel concept",
abstract = "Combination chemotherapy remains the major current treatment of non- Hodgkin's lymphoma. B-cell lymphoma often has tumor-specific surface immunoglobulins called idiotypes. Clinical trials using murine monoclonal anti-idiotype antibodies as a targeting approach have shown some success. I describe a novel concept of using idiotype-specific peptides as an alternative targeting approach for the treatment of B-cell lymphoma. In brief, octapeptides that bind to the surface idiotype of the B-cell lymphoma are isolated from a large synthetic peptide library (106 to 107 peptides). Once the sequence of a tumor-specific octapeptide ligand is defined, large quantities can be synthesized and conjugated with a radionuclide (such as iodine 131). This should permit highly specific destruction of lymphoma cells that bind the labeled peptide. The theoretic advantages of this approach over the previous use of anti-idiotype antibodies are addressed.",
author = "Kit Lam",
year = "1993",
language = "English (US)",
volume = "158",
pages = "475--479",
journal = "Western Journal of Medicine",
issn = "0093-0415",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Treatment of B-cell lymphoma using peptides - A novel concept

AU - Lam, Kit

PY - 1993

Y1 - 1993

N2 - Combination chemotherapy remains the major current treatment of non- Hodgkin's lymphoma. B-cell lymphoma often has tumor-specific surface immunoglobulins called idiotypes. Clinical trials using murine monoclonal anti-idiotype antibodies as a targeting approach have shown some success. I describe a novel concept of using idiotype-specific peptides as an alternative targeting approach for the treatment of B-cell lymphoma. In brief, octapeptides that bind to the surface idiotype of the B-cell lymphoma are isolated from a large synthetic peptide library (106 to 107 peptides). Once the sequence of a tumor-specific octapeptide ligand is defined, large quantities can be synthesized and conjugated with a radionuclide (such as iodine 131). This should permit highly specific destruction of lymphoma cells that bind the labeled peptide. The theoretic advantages of this approach over the previous use of anti-idiotype antibodies are addressed.

AB - Combination chemotherapy remains the major current treatment of non- Hodgkin's lymphoma. B-cell lymphoma often has tumor-specific surface immunoglobulins called idiotypes. Clinical trials using murine monoclonal anti-idiotype antibodies as a targeting approach have shown some success. I describe a novel concept of using idiotype-specific peptides as an alternative targeting approach for the treatment of B-cell lymphoma. In brief, octapeptides that bind to the surface idiotype of the B-cell lymphoma are isolated from a large synthetic peptide library (106 to 107 peptides). Once the sequence of a tumor-specific octapeptide ligand is defined, large quantities can be synthesized and conjugated with a radionuclide (such as iodine 131). This should permit highly specific destruction of lymphoma cells that bind the labeled peptide. The theoretic advantages of this approach over the previous use of anti-idiotype antibodies are addressed.

UR - http://www.scopus.com/inward/record.url?scp=0027211126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027211126&partnerID=8YFLogxK

M3 - Article

VL - 158

SP - 475

EP - 479

JO - Western Journal of Medicine

JF - Western Journal of Medicine

SN - 0093-0415

IS - 5

ER -